Physician profile
Raysa Ortiz
NPI 1154058956
$658.95
in general payments reported to CMS, 2019-2025
14 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $160 · 2023: $130 · 2024: $253 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $125.00 | 2024 | |
| Novo Nordisk INC | $124.77 | 2022 | |
| Merck Sharp & Dohme LLC | $122.89 | 2022-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Cranial Technologies, INC | $44.79 | 2024-2025 | Doc Band |
| Alk-Abello, INC | $29.82 | 2024-2025 | Neffy, Odactra, Grastek |
| Phadia US INC. | $29.38 | 2023-2025 | Immunocap |
| Aytu Biopharma, INC. | $27.78 | 2024-2025 | Karbinal |
| Astrazeneca Pharmaceuticals LP | $26.45 | 2024 | Flumist Quadrivalent |
| Cumberland Pharmaceuticals, INC. | $25.98 | 2024 | Kristalose |
| Hologic Sales and Service, LLC | $24.41 | 2023 | Aptima |
| Sobi, INC | $24.16 | 2023 | |
| Sanofi Pasteur INC. | $22.71 | 2022 | |
| Seqirus USA INC | $16.84 | 2023 | Flucelvax Quadrivalent |
| Alexion Pharmaceuticals, INC. | $13.97 | 2025 | Koselugo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raysa Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.